Pharmaceutical potential of active compounds from plants
A comprehensive review on Alzhemier disease and future possibilities
Keywords:
Alzheimer disease, causes, diagnosis, symptoms, treatmentAbstract
Alzheimer's illness (AD) is an issue that causes cell degeneration in the cerebrum and is the primary driver of dementia, which is described by a lessening in thought and freedom in private everyday exercises. Promotion is viewed as a multifactorial sickness: two primary speculations were proposed as a reason for theories of commercials, cholinergic and amyloids. Moreover, a few gamble factors, like expanding age, hereditary variables, head wounds, vascular illnesses, contaminations, and natural elements, assume a part in the infection. At present, there are just two sorts of meds endorsed to treat AD, including cholinesterase compound inhibitors and N-methyl D-aspartate (NMDA) bad guys, who are powerful just in the treatment of AD side effects, yet don't fix or keep you from disease. Today, research is zeroing in on the comprehension of AD pathology focused on a few systems, like strange tau protein digestion, β-amyloid, fiery reaction, and cholinergic and free extreme harm, with the target of creating effective medicines to stop or alter the course of the declaration. This survey presently examines accessible drugs and future hypotheses for the advancement of new treatments for AD and normal mixtures.
Downloads
References
Anand P, Singh B (2013) A review on cholinesterase inhibitors for Alzheimer’s disease. Arch. Pharmacal Res.
Andrade S, Ramahalo M.J, Loureiro, JA Pereira (2019) M.C. Interaction of natural compounds with bio membrane model, Colloids Surf. B Bio interfaces A biophysical approach for the Alzheimer’s disease therapy 180, 83–92.
Annweile C, Fantino B, Perot-Schinkel E, Thiery S, Gautier J, Beauchet O (2011) Alzheimer’s disease input of vitamin D with memantine assay (AD-IDEA trial): Study protocol for a randomized controlled trial. Trials 12, 230.
Annweiler C (2016) Vitamin D in dementia prevention. Ann. N. Y. Acad. Sci 1367, 57–63.
Annweiler C, Herrmann FR, Fantino B, Brugg B, Beauchet O (2012) Effectiveness of the Combination of Memantine Plus Vitamin D on Cognition in Patients with Alzheimer Disease: A Pre-Post Pilot Study. Cogn. Behav. Neurol.25, 121–127.
Armstrong, RA (2009) The molecular biology of senile plaques and neurofibrillary tangles in Alzheimer’s disease. Folia Neuropathology 47, 289–299.
Armstrong, RA (2019) Risk factors for Alzheimer’s disease. Folia Neuropathology 57, 87–105.
Asha H (2017) A Review: Natural Compounds as Anti-Alzheimer´s Disease Agents. Curr. Nutr. Food Sci 13, 247–254.
Babic T Geriatr J (1999) The cholinergic hypothesis of Alzheimer’s disease: A review of progress, Neurosurg Psychiatry 67, 558.
Baddeley (1978) AD 'The trouble with levels: a re-examination of Craik and Lockhart's framework for memory research', Psychological Review. 85: 139-152
Baddeley (1999) A.D. 'Working memory', Science 255: 556-559.
Bekris LM, Yu CE, Bird TD, Tsuang DW, Geriatr J (2010) Genetics of Alzheimer disease, Psychiatry Neurol 23, 213–227.
Biron JP (1998) Neurofibrillary tangles and Alzheimer’s disease. Eur. Neurol 40, 130–140.
Blass JP, Gruenburg EM (1985) Alzheimer’s disease. Dis a Mon, Epidemiology of senile dementia 31, 1–69.
Cho HS, Huang LK, Lee YT, Chan L, Hong CT (2018) Suboptimal baseline serum Vitamin B12 is associated with cognitive decline in people with Alzheimer’s disease undergoing cholinesterase inhibitor treatment. Front, Neurol. 2018, 9, 325.
Cipriani G, Dolciotti C, Picchi L, Bonuccelli U, (2011) Alzheimer and his disease, A brief history. Neurol. Sci, Off. J. Ital. Neurol. Soc. Ital. Soc. Clin. Neurophysiol 32, 275–279.
Cras P, Kawai M, Lowrey D, Gonzalez-DE Whitt P, Greenberg B, Perry G (1991) Senile plaque neurites in Alzheimer disease accumulate amyloid precursor protein. Proc. Natl. Acad. Sci. USA 88, 7552–7556.
David B, Wolfender JL, Dias DA (2015) The pharmaceutical industry and natural products: Historical status and new trends. Phytochem. Rev 14, 299–315.
De-Paula VJ, Radanovic M, Diniz BS, Forlenza OV, (2012) Alzheimer’s disease. Sub-Cell. Biochem65, 329–352.
Dey A, Bhattacharya R, Mukherjee A, Pandey DK, (2017) Natural products against Alzheimer’s disease: Pharmaco-therapeutics and biotechnological interventions. Biotechnology Adv 35, 178–216.
Dursun E, Gezen-Ak D (2018) Vitamin D basis of Alzheimer’s disease: From genetics to biomarkers, Hormones 18, 7–15.
Galasko DR, Peskind E, Clark CM, (2012) Antioxidants for Alzheimer disease: A randomized clinical trial with cerebrospinal fluid biomarker measures. Arch. Neurol. 69, 836–841.
Grant WB, Campbell A, Itzhaki RF, Savory J (2002) The significance of environmental factors in the etiology of Alzheimer’s disease. J. Alzheimer’s Dis. Jad 4, 179–189.
Guerreiro R, Bras J (2015) The age factor in Alzheimer’s disease. Genome Med 7, 106.
Hampel H, Mesulam MM, Cuello AC, Farlow MR, Giacobini Grossberg GT, Khachaturian AS, Vergallo A, Cavedo E, Snyder PJ (2018) The cholinergic system in the pathophysiology and treatment of Alzheimer’s disease. Brain A J. Neurol 141, 1917–1933.
Hou Y, Dan X, Babbar M, Wei Y, Hasselbalch SG, Croteau DL, Bohr VA (2019) Ageing as a risk factor for neurodegenerative disease. Nat. Rev. Neurol 15, 565–581.
Jarosz M (2017) Normy Zywienia dla Populacji Polski Instytut Zywno´sci i Zywienia: Warsaw, Poland (In Polish: Nutrition standards for the Polish population)
Jatoi S, Hafeez A, Riaz SU, Ali A, Ghauri MI, Zehra M (2020) Low Vitamin B12 levels: An underestimated cause of minimal cognitive impairment and dementia. Cureus 12, e6976.
Khanahmadi M, Farhud DD, Malmir M (2015) Genetic of Alzheimer’s disease: A narrative review article. Iran. J. Public Health 44, 892–90
Livingston G, Huntley J, Sommerlad A, Ames D, Ballard Banerjee S, Brayne C, Burns A, Cohen-Mansfield J, Cooper C (2020) Dementia prevention, intervention, and care: report of the Lancet Commission. Lancet 396, 413–446.
Lleo A, Nunez-Llaves, R Alcolea D, Chiva C, Balateu-Panos D, Colom-Cadena Gomez-Giro G, Munoz L, Querol-Vilaseca M, Pegueroles (2019) Changes in synaptic proteins precede neurodegeneration markers in preclinical Alzheimer’s disease cerebrospinal fluid. Mol. Cell. Proteom. Mcp 18, 546–560.
McKhannG, Drachman D, Folstei, M, Katzman R, Price D, Stadlan EM (1984) Clinical diagnosis of Alzheimer’s disease: Report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer’s Disease. Neurology 34, 939–944.
Metaxas A Kempf SJ (2016) Neurofibrillary tangles in Alzheimer’s disease: Elucidation of the molecular mechanism by immunohistochemistry and tau protein phospho-proteomics. Neural Regen. Res. 1579–1581.
Monczor M (2005) Diagnosis and treatment of Alzheimer’s disease. Curr. Med. Chem. Cent. Nerv. Syst. Agents 5, 5–13.
Neugroschl J, Wang S (2011) Alzheimer’s disease: Diagnosis and treatment across the spectrum of disease severity. Mt. Sinai J. Med. N. Y. 78, 596–612.
Paroni G. Bisceglia P, Seripa D (2019) Understanding the amyloid hypothesis in Alzheimer’s disease. J. Alzheimer’s Dis. Jad 68, 493–510.
Przybelski R, Agrawal, S, Krueger D, Engelke JA, Walbrun F, Binkley N (2008) Rapid correction of low vitamin D status in nursing home residents. Osteoporos. Int. 19, 1621–1628.
Rasool M, Malik A, Qureshi MS, Manan A, Pushparaj PN, Asif M, Qazi MH, Qazi AM, Kamal MA, Gan SH (2014) Recent Updates in the Treatment of Neurodegenerative Disorders Using Natural Compounds. Evid. Based Complement. Altern. Med. 979730.
Rathmann KL, Conner CS (1984) Alzheimer’s disease: Clinical features, pathogenesis, and treatment. Drug Intell. Clin. Pharm. 18, 684–691.
Ricciarelli R, Fedele, E (2017) The amyloid cascade hypothesis in Alzheimer’s disease: It’s time to change our mind. Curr. Neuropharmacol.15, 926–935.
Riedel BC, Thompson PM, Brinton RD. (2016) Age, APOE and sex: Triad of risk of Alzheimer’s disease. J. Steroid Biochem. Mol. Biol. 160, 134–147.
Santos CY, Snyder PJ, Wu WC, Zhang M, Echeverria A, Alber J (2017) Pathophysiologic relationship between Alzheimer’s disease, cerebrovascular disease, and cardiovascular risk: A review and synthesis. Alzheimer’s Dement. 7, 69–87.
Schachter AS. Davis KL (2000) Alzheimer’s disease. Dialogues Clin. Neurosci. 2, 91–100.
Serrano-Pozo A, Frosch MP, Masliah E, Hyman BT (2011) Neuropathological alterations in Alzheimer disease. Cold Spring Harb. Perspect. Med.1, a006189.
Shen L (2015) Ji H.-F. Associations between Homocysteine, Folic Acid, Vitamin B12 and Alzheimer’s Disease: Insights from Meta-Analyses. J. Alzheimer Dis. 46, 777–790
Silva T, Reis J, Teixeira J. Borges F. (2014) Alzheimer’s disease, enzyme targets and drug discovery struggles: From natural products to drug prototypes. Ageing Res. Rev.15, 116–145.
Singh SK, Srivastav SY, adav AK, Srikrishna S, Perry G (2016) Overview of Alzheimer’s disease and some therapeutic approaches targeting a beta by using several synthetic and herbal compounds. Oxidative Med. Cell. Longev.7361613.
Stampfer MJ (2006) cardiovascular disease and Alzheimer’s disease: Common links. J. Intern. Med. 260, 211–223.
Tabaton M, Piccini A (2005) Role of water-soluble amyloid-beta in the pathogenesis of Alzheimer’s disease. Int. J. Exp. Pathol, 86, 139–145.
Tarawneh RD, Angelo G, Crimmins D, Herries E, Griest T, Fagan AM, Zipfel GJ, Ladenson JH, Morris JC, Holtzman DM (2016) Diagnostic and prognostic utility of the synaptic marker neurogranin in Alzheimer Disease. JAMA Neurol. 73, 561–571.
Terry RD, Davies P (1980) Dementia of the Alzheimer type. Annu. Rev. Neurosci.3, 77–95.
Van Cauwenberghe C, Van Broeckhoven C, Sleegers K (2016) The genetic landscape of Alzheimer disease: Clinical implications and perspectives. Genet. Med. Off. J. Am. Coll. Med Genet. 18, 421–430.
Wainaina MN, Chen Z, Zhong C (2014) Environmental factors in the development and progression of late-onset Alzheimer’s disease. Neurosci. Bull.30, 253–270.
Wattmo C, Minthon L, Wallin AK (2016) Mild versus moderate stages of Alzheimer’s disease: Three-year outcomes in a routine clinical setting of cholinesterase inhibitor therapy. Alzheimer’s Res. Ther, 8, 7.
Yaari R, FleisherAS, Tariot P N (2011) Updates to diagnostic guidelines for Alzheimer’s disease. Prim. Care Companion Cns Disord. 13, 11f01262.
Yiannopoulou KG, Papageorgiou SG (2020) Current and future treatments in Alzheimer disease: An update. J. Cent. Nerv. Syst. Dis. 12.
Published
How to Cite
Issue
Section
Copyright (c) 2022 International journal of health sciences
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
Articles published in the International Journal of Health Sciences (IJHS) are available under Creative Commons Attribution Non-Commercial No Derivatives Licence (CC BY-NC-ND 4.0). Authors retain copyright in their work and grant IJHS right of first publication under CC BY-NC-ND 4.0. Users have the right to read, download, copy, distribute, print, search, or link to the full texts of articles in this journal, and to use them for any other lawful purpose.
Articles published in IJHS can be copied, communicated and shared in their published form for non-commercial purposes provided full attribution is given to the author and the journal. Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgment of its initial publication in this journal.
This copyright notice applies to articles published in IJHS volumes 4 onwards. Please read about the copyright notices for previous volumes under Journal History.
